Progestogen for preventing miscarriage

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Haas, David M ^a   Ramsey, Patrick S ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; PLACEBO;

BIRTH WEIGHT; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FETUS DISEASE; GESTATIONAL AGE; HUMAN; META ANALYSIS; NEWBORN DEATH; OUTCOME ASSESSMENT; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SPONTANEOUS ABORTION; SYSTEMATIC REVIEW; TREATMENT PLANNING; VIRILIZATION; ABORTION, HABITUAL; ABORTION, SPONTANEOUS; FEMALE; PREGNANCY; SECOND TRIMESTER PREGNANCY; RECURRENT ABORTION;

ABORTION, HABITUAL; ABORTION, SPONTANEOUS; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PROGESTINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84899470293     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003511.pub3     Document Type: Review

References (69)

1. Berle P, Budenz M, Michaelis J. Is hormonal therapy still justified in imminent abortion?. Zeitschrift fur Geburtshilfe und Perinatologie 1980;184:353-8.
2. Corrado F, Dugo C, Cannata M, Di Bartolo M, Scilipoti A, Stella N. A randomised trial of progesterone prophylaxis after midtrimester amniocentesis. European Journal of Obstetrics & Gynecology and Reproductive Biology 2002;100(2):196-8.
3. El Zibdeh M. Randomized clinical trial comparing the efficacy of dydrogesterone and human chorionic gonadotropin. Climacteric 2002;5(Suppl 1):136.
4. El Zibdeh M. Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with progesterone and human chorionic gonadotropin (hCG). Fertility and Sterility 1998;70(3 Suppl 1):S77-S78.
5. El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. Journal of Steroid Biochemistry & Molecular Biology 2005;97(5):431-4.
6. Gerhard I, Gwinner B, Eggert-Kruse W, Runnebaum B. Double-blind controlled trial of progesterone substitution in threatened abortion. Biological Research in Pregnancy and Perinatology 1987;8:26-34.
7. Goldzieher JW. Double-blind trial of a progestin in habitual abortion. JAMA 1964;188(7):651-4.
8. Klopper A, MacNaughton M. Hormones in recurrent abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth 1965;72:1022-8.
9. Le Vine L. Habitual abortion. A controlled clinical study of progestational therapy. Western Journal of Surgery 1964;72:30-6.
10. MacDonald RR, Goulden R, Oakey RE. Cervical mucus, vaginal cytology and steroid excretion in recurrent abortion. Obstetrics & Gynecology 1972;40(3):394-402.
11. Moller K, Fuchs F. Double blind controlled trial of 6-methyl-17-acetoxyprogesterone in threatened abortion. Journal of Obstetrics and Gynaecology of the British Commonwealth 1965;72:1042-4.
12. Nyboe Anderson A, Popovic-Todorovic B, Schmidt K, Loft A, Lindhard A, Hojgaard A, et al.Progesterone supplement during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Human Reproduction 2002;17(2):357-61.
13. Reijnders FJL, Thomas CMG, Doesburg WH, Rolland R, Eskes TKAB. Endocrine effects of 17 alpha-hydroxyprogesterone caproate during early pregnancy: a double-blind clinical trial. British Journal of Obstetrics and Gynaecology 1988;95:462-8.
14. Shearman R, Garrett W. Double-blind study of effect of 17-hydroxyprogesterone caproate on abortion rate. British Medical Journal 1963;1:292-5.
15. Swyer GIM, Daley D. Progesterone implantation in habitual abortion. British Medical Journal 1953;1:1073-86.
16. Tognoni G, Ferrario L, Inzalaco M, Crosignani P. Progestogens in threatened abortion. Lancet 1980;2(8206):1242-3.
17. Brenner W, Hendricks C. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation labour. American Journal of Obstetrics and Gynecology 1962;83(8):1094-8.
18. Check J, Wu C-H, Adelson H. Decreased abortion in HMG-induced pregnancies. International Journal of Fertility 1985;30(3):45-7.
19. Check J, Chase J, Nowroozi K, Wu C, Adelson H. Progesterone therapy to decrease first-trimester spontaneous abortions in previous aborters. International Journal of Fertility 1987;32(3):192-9.
20. Check J, Chase J, Wu C, Adelson H, Teichman M, Rankin A. The efficacy of progesterone in achieving successful pregnancy: prophylactic use during luteal phase in anovulatory women. International Journal of Fertility 1987;32(2):135-8.
21. Check JH, Tarquini P, Gandy P, Lauer C. A randomized study comparing the efficacy of reducing the spontaneous abortion rate following lymphocyte immunotherapy and progesterone treatment vs progesterone alone in primary habitual aborters. Gynecologic and Obstetric Investigation 1995;39:257-61.
22. Clifford K, Rai R, Watson H, Franks S, Regan L. Does suppressing luteinising hormone secretion reduce the miscarriage rate? Results of a randomised controlled trial. BMJ 1996;312:1508-11.
23. Daya S, Ward S, Burrows E. Progesterone profiles in luteal phase defect cycles and outcome of progesteron treatment in patients with recurrent spontaneous abortion. American Journal of Obstetrics and Gynecology 1988;158(2):225-32.
24. Fuchs F, Olsen P. An attempted double-blind controlled trial of progesterone therapy in habitual abortion. Ugeskrift for Laeger 1966;128:1461-2.
25. Johnson J, Austin K, Jones G, Davis G, King T. Efficacy of 17 alpha-hydroxyprogesterone caproate on the prevention of premature labour. New England Journal of Medicine 1975;298(14):675-80.
26. Kyrou D, Fatemi HM, Zepiridis L, Riva A, Papanikolaou EG, Tarlatzis BC, et al.Does cessation of progesterone supplementation during early pregnancy in patients treated with recFSH/GnRH antagonist affect ongoing pregnancy rates? A randomized controlled trial. Human Reproduction 2011;26(5):1020-4.
27. Norman JE. Double blind randomised placebo controlled study of progesterone for the prevention of preterm birth in twins (STOPPIT). National Research Register. www.nrr.nhs.uk (accessed 6 July 2006).
28. Prietl G, Diedrich K, Van der Ven HH, Luckhaus J, Krebs D. The effect of 17alpha-hydroxyprogesterone caproate/oestradiol valerate on the development and outcome of early pregnancies following in vitro fertilization and embryo transfer: a prospective and randomized controlled trial. Human Reproduction 1992;7(1):1-5.
29. Rock J, Colston Wentz A, Cole K, Kimball A, Zacur H, Early S, et al.Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertility and Sterility 1985;44(1):17-9.
30. Shu J, Miao P, Wang RJ. Clinical observation on effect of Chinese herbal medicine plus human chorionic gonadotropin and progesterone in treating anticardiolipin antibody-positive early recurrent spontaneous abortion. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi//Chinese Journal of Integrated Traditional and Western Medicine 2002;22(6):414-6.
31. Sidelnikova VM, Demidova EM, Borisova IF, Dondukova TM, Absava GI, Korkhov VV. The use of acetomepegrenol in the therapy of threatened abortion. Akusherstvo i Ginekologiia 1990;66(9):37-40.
32. Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. Randomized prospective trial comparing supplementation of the luteal phase and of early pregnancy by natural progesterone given by intramuscular or vaginal administration. Revue Francaise de Gynecologie et d Obstetrique 1992;87:507-16.
33. Sondergaard F, Ottesen B, Detlefsen GU, Schierup L, Pederson SC, Lebech PE. Progesterone treatment of cases of threatened pre-term delivery in women with a low level of plasma progesterone. Contraception, Fertilite, Sexualite 1985;13(12):1227-31.
34. Turner SJ, Mizock GB, Feldman GL. Prolonged gynecologic and endocrine manifestations subsequent to administration of medroxyprogesterone acetate during pregnancy. American Journal of Obstetrics and Gynecology 1966;95:222-7.
35. Coomarasamy A. First trimester progesterone therapy in women with a history of unexplained recurrent miscarriages: a randomised double-blind placebo-controlled multi-centre trial (The PROMISE [PROgesterone in recurrent MIScarriagE] Trial). http://www.controlled-trials.com/ISRCTN92644181 (accessed 11.01.2012).
36. Raddatz G. Habitual abortion study: oral dydrogesterone treatment during pregnancy in women with recurrent miscarriage. http://clinicaltrials.gov/ct2/show/NCT00193674 (accessed 21 March 2006).
37. Walch K, Hefler L, Nagele F. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial. Journal of Maternal-Fetal & Neonatal Medicine 2005;18(4):265-9.
38. Alfirevic Z, Stampalija T, Roberts D, Jorgensen AL. Cervical stitch (cerclage) for preventing preterm birth in singleton pregnancy. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: ]
39. Atkin LC, Arcelus M, Fernandez A, Tolbert K. La Psicologia en el Ambito Perinatal. Mexico D.F: INPER, 1988.
40. Bamigboye AA, Morris J. Oestrogen supplementation, mainly diethylstilbestrol, for preventing miscarriages and other adverse pregnancy outcomes. Cochrane Database of Systematic Reviews 2003, Issue 3. [DOI: ]
41. Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation. 9th Edition. Philadelphia: Lippincott Williams & Wilkins, 2011.
42. Burgoyne PS, Holland K, Stephens R. Incidence of numerical chromosome anomalies in human pregnancy estimation from induced and spontaneous abortion data. Human Reproduction 1991;6(4):555-65.
43. Coomarasamy A, Truchanowicz EG, Rai R. Does first trimester progesterone prophylaxis increase the live birth rate in women with unexplained recurrent miscarriages?. BMJ 2011;342:d1914.
44. Coulam CB. Epidemiology of recurrent spontaneous abortion. American Journal of Reproductive Immunology 1991;26:23-7.
45. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ Books, 2001.
46. Dyregrove A, Mathieson SB. Stillbirth, neonatal death and SIDS: parental reactions. Scandanavian Journal of Psychology 1987;28:104-14.
47. Goldstein P, Berrier J, Rosen S, Sacks HS, Chalmers TC. A meta-analysis of randomised control trials of progestational agents in pregnancy. British Journal of Obstetrics and Gynaecology 1989;96:265-74.
48. Grudzinskas JG. Endocrinocolgical and metabolical assesssment of early pregnancy. In: Chamberlain G editor(s). Tumbull's Obstetrics. London: Pearson Professional Ltd, 1995.
49. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd.
50. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
51. Howie PG. Abortion and ectopic pregnancy. In: Whitfield CR editor(s). Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates. Oxford: Blackwell Science Ltd, 1995.
52. Karamadian LM, Grimes DA. Luteal phase deficiency. Effect of treatment on pregnancy rates. American Journal of Obstetrics and Gynecology 1992;167:1391-8.
53. Keirse M J. Progestogen administration in pregnancy may prevent preterm delivery. British Journal of Obstetrics and Gynaecology 1990;97(2):149-54.
54. Lede R, Duley L. Uterine muscle relaxant drugs for threatened miscarriage. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: ]
55. McBride WZ. Spontaneous abortion. American Family Physician 1991;43:175-82.
56. Morley LC, Simpson N, Tang T. Human chorionic gonadotrophin (hCG) for preventing miscarriage. Cochrane Database of Systematic Reviews 2013, Issue 1. [DOI: ]
57. Neilson JP, Hickey M, Vazquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: ]
58. Porter TF, LaCoursiere Y, Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: ]
59. Regan L, Braude PB, Trembath PR. Influences of past reproductive performance on risk of spontaneous abortion. BMJ 1989;299:541-5.
60. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
61. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.
62. Royal College of Obstetricians and Gynaecologists. The management of recurrent miscarriage. http://www.rcog.org.uk/guidelines/recurrent.html (accessed 2001).
63. Rumbold A, Middleton P, Pan N, Crowther CA. Vitamin supplementation for preventing miscarriage. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: ]
64. Simpson JL. Fetal wastage. In: Gabe SG, Simpson JL editor(s). Obstetrics. Normal and Problem Pregnancies. New York: Churchill Livingstone Inc, 1991.
65. Szabo I, Szilagyi A. Management of threatened abortion. Early Pregnancy 1996;2(4):233-40.
66. Vance JC, Foster WJ, Najman JM, Embelton, Thearle MJ, Hogden FM. Early parental responses to sudden infant death, stillbirth or neonatal death. Medical Journal of Australia 1991;155(5):292-7.
67. Woods JR, Esposito JL. Pregnancy Loss: Medical Therapeutics and Practical Considerations. Baltimore: Williams and Wilkins, 1987.
68. Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: ]
69. Oates-Whitehead RM, Haas DM, Carrier JAK. Progestogen for preventing miscarriage. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: ]